Openfund

CORDIS · SCREEN4CARE

Shortening the path to rare disease diagnosis by using newborn genetic screening and digital technologies

Code
SCREEN4CARE
Programme
H2020
Call
IMI2-2020-23-05
Status
SIGNED
Period
2021-10-01 – 2026-09-30
Total cost (whole consortium)26 247 174 €
EU contribution (whole consortium)11 938 569 €
EU contribution to Bulgarian participants226 721 €

Official data · CORDIS · synced 2026-10-18 03:29 · official record

Participants

OrganisationsRoleCountryGrant
UNIVERSITA DEGLI STUDI DI FERRARAcoordinatorIT691 786 €
UNIVERSITAETSKLINIKUM FREIBURGparticipantDE1 119 459 €
CHARITE - UNIVERSITAETSMEDIZIN BERLINparticipantDE1 049 100 €
UNIVERSITAETSMEDIZIN GOETTINGEN - GEORG-AUGUST-UNIVERSITAET GOETTINGEN - STIFTUNG OEFFENTLICHEN RECHTSparticipantDE931 361 €
OSPEDALE PEDIATRICO BAMBINO GESUparticipantIT753 848 €
EURORDIS - RARE DISEASES EUROPEparticipantFR736 895 €
UPPSALA UNIVERSITETparticipantSE675 785 €
UNIVERSITAET BERNparticipantCH659 656 €
SYDDANSK UNIVERSITETparticipantDK651 996 €
FINDZEBRA APSparticipantDK493 646 €
UNIVERSITATSKLINIKUM ERLANGENparticipantDE490 000 €
EURICE EUROPEAN RESEARCH AND PROJECT OFFICE GMBHparticipantDE485 375 €
GNX DATA SYSTEMS LTDparticipantIL392 000 €
CONSORCIO PARA LA EXPLOTACION DEL CENTRO NACIONAL DE ANALISIS GENOMICOparticipantES388 544 €
UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLINparticipantIE373 014 €
MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EVparticipantDE342 528 €
SBA RESEARCH GEMEINNUTZIGE GMBHparticipantAT309 750 €
SITEM-INSEL AGparticipantCH308 218 €
RESEARCH INSTITUTE AG & CO KGparticipantAT273 410 €
LUDWIG BOLTZMANN GESELLSCHAFT OSTERREICHISCHE VEREINIGUNG ZUR FORDERUNG DER WISSENSCHAFTLICHEN FORSCHUNGparticipantAT203 040 €
CENTRE HOSPITALIER REG UNIVERSITAIRE DIJONparticipantFR142 861 €
CONSORZIO FUTURO IN RICERCAparticipantIT120 000 €
BULGARIAN ASSOCIATION FOR PERSONALIZED MEDICINEparticipantBG113 471 €
BULGARIAN ASSOCIATION FOR PROMOTION OF EDUCATION AND SCIENCEparticipantBG113 250 €
COPENHAGEN BUSINESS SCHOOLparticipantDK62 106 €
UNIVERSITA DEGLI STUDI DI SIENAparticipantIT56 045 €
FUNDACIO CENTRE DE REGULACIO GENOMICAparticipantES1 425 €
PTC THERAPEUTICS INTERNATIONAL LIMITEDparticipantIE0 €
UCB BIOPHARMAparticipantBE0 €
PROQR THERAPEUTICS NVparticipantNL0 €
TAKEDA PHARMACEUTICALS INTERNATIONAL AGparticipantCH0 €
LYSOGENEparticipantFR0 €
WALLAC OYparticipantFI0 €
PFIZER LIMITEDparticipantUK0 €
SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENTparticipantFR0 €
F. HOFFMANN-LA ROCHE AGparticipantCH0 €
NOVARTIS PHARMA AGparticipantCH0 €
ILLUMINA CAMBRIDGE LIMITEDparticipantUK0 €
UNIVERSITATSKLINIKUM BONNparticipantDE0 €
UNIVERZITA KARLOVAparticipantCZ0 €
NOVO NORDISK A/SparticipantDK0 €

Description

In the EU alone, according to the Orphanet DB (https://pubmed.ncbi.nlm.nih.gov/31527858/), 30 million persons, 3,5-6% of the general population, are affected by one of the 6,172 different rare diseases (RDs) of which 72% are genetic and 70% affect children. The path to diagnosis for people suffering from a RD is burdensome, often severely delayed by a diagnostic odyssey. Lack of timely diagnosis affects disease management, family planning, identification of potential beneficial treatments and / or clinical trials. This unacceptable situation does not meet the concept of equity for EU citizens, and requires rapid, structured, and cost-effective corrective actions. The Screen4Care (S4C) consortium will leverage the genomic and digital advent to develop and pilot genetic NBS and AI-guided symptom recognition algorithms, while accounting for all relevant legal, regulatory and ethical considerations. S4C aims to harmonize the results of existing efforts in a horizon scan, by looking at the totality of the available data resources, diagnostic algorithms, and other initiatives with similar ultimate goals.The genetic NBS will interrogate 1) currently treatable RDs (TREAT-map gene panel), 2) actionable RDs (ACT-map gene panel) in 18.000 new-borns in 3 EU countries (D, It, and Cz). Further, S4C will offer whole genome sequencing (WGS) to early symptomatic babies, tested negatively during panel-based NBS to identify known NBS-escaped RDs and novel genes/phenotypes. S4C will also provide two digital diagnosis support systems for RD on the basis of features and symptom complexes: 1) federated ML- and literature-evidence-based algorithm for continuous and automated screening of EHR and 2) meta symptom checker with virtual clinics for patients and HCP offering the possibility of increased accuracy of diagnosis and ongoing supports. Our ambitious goal is to evaluate the validity of our multi-pronged approach to shorten the time to diagnosis for all patients affect by RDs, improve value-based healthcare resource utilization, and hopefully reduce the suffering of millions of European citizens.

Official data · CORDIS · synced 2026-10-18 03:29 · official record · Licence: © European Union, CC BY 4.0 (Commission reuse policy).